
Quarterly report 2025-Q3
added 11-14-2025
ENDRA Life Sciences Net Debt 2011-2026 | NDRA
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt ENDRA Life Sciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.37 M | -8.78 M | -6.54 M | -5.47 M | -6.47 M | -5.6 M | 805 K | -19.1 K | -156 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 805 K | -8.78 M | -4.07 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
Biomerica
BMRA
|
-1.94 M | $ 2.13 | -2.74 % | $ 4.89 M | ||
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
Castle Biosciences
CSTL
|
-108 M | $ 25.75 | 3.0 % | $ 715 M | ||
|
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 195.6 | 0.17 % | $ 21.7 B | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | ||
|
DexCom
DXCM
|
-842 M | $ 65.94 | -1.51 % | $ 25.7 B | ||
|
Co-Diagnostics
CODX
|
-11.9 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
-916 M | $ 104.91 | - | $ 19.8 B | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 16.33 | 5.29 % | $ 494 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
Charles River Laboratories International
CRL
|
1.98 B | $ 158.0 | 2.86 % | $ 7.83 B | ||
|
IQVIA Holdings
IQV
|
12 B | $ 166.96 | 0.54 % | $ 28.7 B | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
1.19 M | $ 1.46 | 26.96 % | $ 1.86 M | ||
|
Interpace Biosciences
IDXG
|
105 K | $ 1.71 | 0.73 % | $ 7.5 M | ||
|
IDEXX Laboratories
IDXX
|
222 M | $ 578.51 | 0.22 % | $ 46.5 B | ||
|
Agilent Technologies
A
|
1.24 B | $ 112.02 | 0.65 % | $ 34.1 B | ||
|
Illumina
ILMN
|
-494 M | $ 123.79 | -0.43 % | $ 19.7 B | ||
|
ICON Public Limited Company
ICLR
|
4.63 B | $ 100.35 | 0.65 % | $ 8.28 B | ||
|
DarioHealth Corp.
DRIO
|
9.37 M | $ 7.5 | -6.13 % | $ 29.9 M | ||
|
Guardant Health
GH
|
1.15 B | $ 84.9 | -0.33 % | $ 10.6 B | ||
|
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | ||
|
CareDx, Inc
CDNA
|
-39.2 M | $ 17.56 | 2.39 % | $ 936 M | ||
|
Lantheus Holdings
LNTH
|
213 M | $ 75.73 | -0.92 % | $ 5.11 B | ||
|
Celcuity
CELC
|
82.8 M | $ 106.75 | 0.67 % | $ 4.21 B | ||
|
Medpace Holdings
MEDP
|
-360 M | $ 456.93 | 0.98 % | $ 13.2 B | ||
|
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 264.42 | 0.54 % | $ 22 B | ||
|
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
2.06 B | $ 1 239.07 | 2.87 % | $ 25.5 B | ||
|
Myriad Genetics
MYGN
|
115 M | $ 4.66 | 1.75 % | $ 432 M | ||
|
NeoGenomics
NEO
|
187 M | $ 8.1 | 1.76 % | $ 1.04 B | ||
|
National Research Corporation
NRC
|
71.3 M | $ 17.51 | 1.1 % | $ 392 M | ||
|
Natera
NTRA
|
-177 M | $ 200.09 | 2.46 % | $ 19.7 B | ||
|
OPKO Health
OPK
|
-411 M | $ 1.15 | 2.68 % | $ 798 M | ||
|
Pacific Biosciences of California
PACB
|
-6.67 M | $ 1.39 | 4.51 % | $ 417 M | ||
|
RadNet
RDNT
|
359 M | $ 61.74 | 0.41 % | $ 4.64 B | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B |